

#ForOurFuture

Contents

For Our Future: Investment Opportunity 2026–2030	2
KEY MESSAGES	3
SOCIAL POST SUGGESTIONS.....	6
DIGITAL ASSETS	8
RESOURCES	8
VOICES OF SUPPORT	8
About Gavi, the Vaccine Alliance	9
DEEP DIVE MESSAGES	10
Global health security and outbreaks	10
Co-financing and sustainability	10
Innovative financing.....	11
Public-private partnership	12
Shaping global markets	12
African Vaccine Manufacturing Accelerator (AVMA).....	13
Value for money and return on investment (ROI)	13
Human papillomavirus (HPV) vaccine and gender equality.....	14
Malaria vaccine programme	15
Climate and health	15
Science and innovation.....	16
Universal Health Coverage (UHC)	16
Zero-dose children	16
Health system strengthening (HSS).....	17
Immunisation and the Sustainable Development Goals (SDGs)	17
Immunisation and nutrition	19

#ForOurFuture

For Our Future: Investment Opportunity 2026–2030

Gavi's [Investment Opportunity](#) (IO) outlines plans for the Vaccine Alliance to **protect 500 million children**, saving **over 8 million** lives between 2026 and 2030. While Gavi vaccinated 1 billion children between 2000 and 2020, Gavi will accelerate its impact in the years to come, leveraging the latest innovations in vaccines and vaccine delivery to **protect the next billion children in half the time as the first, and against more diseases than ever before**.

Ask

- While Gavi vaccinated 1 billion children between 2000 and 2020, Gavi will **accelerate** its impact in the years to come, leveraging the latest innovations in vaccines and vaccine delivery **to protect the next billion children in half the time as the first, and against more diseases than ever before**.
- Achieving this historic milestone will require effort from all of Gavi's stakeholders, **with donors being asked to provide at least US\$ 9 billion in new funding**.

Investment Opportunity

A fully funded Gavi will enable the Alliance to achieve the following between 2026–2030:

- Immunise at least **500 million** more children, including an estimated 300 million children in Africa
- Save an additional **8–9 million** lives
- Catalyse over **US\$ 4 billion** of financial contributions through **domestic co-financing** and **self-funded** vaccine programmes
- **Stand ready to respond to 150 disease outbreaks** to boost global health security and protect against the threat of future pandemics
- **Reduce prices** across at least **50%** of Gavi's vaccine portfolio, generate up to **US\$ 800 million** of **efficiency savings**
- Generate at least **US\$ 100 billion** in **economic benefits** for Gavi implementing countries
- Facilitate over **1.4 billion individual contacts** between families and health services, enabling **more integrated primary health care and Universal Health Coverage**
- Save **1.5 million** lives through the HPV vaccine by protecting girls against cervical cancer
- Vaccinate over **50 million children** against malaria

Gavi's Investment Opportunity 2026–2030

- **Investment Opportunity documents (English, French and other languages):** <https://www.gavi.org/investing-gavi/resource-mobilisation-process/protecting-our-future#io>
- Five years to save 8 million lives: everything you need to know about Gavi's Investment Opportunity: [link](#)
- Gavi's Investment Opportunity by numbers: [link](#)

#ForOurFuture

KEY MESSAGES

1. Overarching messages

- Since its inception 25 years ago, Gavi, the Vaccine Alliance has **protected a whole generation** – over 1 billion children – against infectious diseases, helping to halve child mortality in the countries it supports. Today, Gavi ensures more than half the world's children have access to life-saving vaccines each and every year.
- Thanks to Gavi's work, over 18 million deaths have been averted, sparing millions of families the suffering of losing a child.
- With vaccinated children more likely to attain an education and live a longer, more productive life, Gavi's work at scale helps build **healthier societies, stronger economies and a better future for all of us**.
- Gavi's work **keeps us all safe** from some of the world's deadliest diseases. The Vaccine Alliance is a vital part of our global defence mechanism against outbreaks, epidemics and pandemics.
- Gavi has achieved this remarkable, life-saving impact by **doing development differently**. Its unique Alliance model is founded on the belief that we are far stronger together than apart, with all partners contributing their fair share – including the countries Gavi serves.
- This is not a traditional 'charity' model; this is **an empowerment model**. All countries pay a share of the cost of their Gavi-supported vaccines. As a country's income grows, its co-financing payments increase to eventually cover 100% of the costs of their own vaccine programmes. The ultimate goal is for all countries to reach this stage – and for Gavi **to put itself out of business**.
- Now, in 2025, Gavi is facing its most ambitious, *its most exciting*, period yet. With implementing countries committed to funding nearly 50% of the costs of their vaccines over the next five years, it needs a broad coalition of donors – governments, the private sector and foundations – to ensure it is fully funded to meet its ambitious objectives and make our world safer, healthier and more prosperous for everyone:
 - To reach **500 million more children** with life-saving vaccines, saving an additional **8–9 million lives**.
 - To enable Gavi to respond to over **150 outbreaks**, its largest investment in health security in response to the twin threats of **climate change** and **antimicrobial resistance**.
 - To reach 50 million children with **malaria vaccines**; protect at least 120 million girls with the **HPV vaccine**, which protects against the main causes of cervical cancer; and to take the fight to other diseases like dengue and tuberculosis as new vaccines become available.
 - To generate at least US\$ 100 billion in **economic benefits**, helping countries to grow and become more self-sufficient.

What's at risk:

- To stop funding Gavi now would be to lose decades of progress and set the world on a dangerous trajectory of increasing vulnerability against an upturn in outbreaks of deadly, yet preventable, diseases.

#ForOurFuture

Doing development differently

- The founding principle of Gavi is that we are far stronger together than apart. Its alliance model is unique, designed to bring the unique comparative advantages of partners to protect children from preventable diseases efficiently and effectively.
- This means bringing together the expertise and reach of the global health community, the implementing power of partner governments, the resources and support of donor governments and foundations, the community-level knowledge and advocacy of civil society, and the innovation and know-how of the private sector. Together, it has achieved much more than it could have by acting alone.
- Our empowerment model has already helped 19 countries transition from Gavi support so that they now fund 100% of their own vaccine programmes. More will follow, and over the next five years, Gavi-supported countries will pay almost 50% of the cost of their vaccine programmes. This is about sustainability and sovereignty: Gavi support is a hand up, not a handout.

What's at risk:

- Gavi's impressive progress in helping to build countries' self-sufficiency and resilience is at a crucial juncture: cutting vital support now could set countries backward on their trajectory and make our world a more dangerous place. We need a fully funded Gavi to see its mission through to completion.

Keeping us all safe

- Gavi helps keep us all safe from some of the world's deadliest diseases. The Vaccine Alliance is a vital, fundamental part of our global defence mechanism against outbreaks, epidemics and pandemics.
- As we now know all too well, diseases do not respect borders. Vaccines are often our first line of defence, stopping the spread of an infection locally before it becomes a health crisis globally.
- This is why Gavi funds the global vaccine stockpiles against deadly infections like Ebola, cholera and yellow fever. It stepped up during the COVID-19 pandemic to help deliver vaccines rapidly and successfully across the globe.
- Right now, Gavi is helping to fight mpox outbreaks across Africa. As the largest provider of mpox vaccines globally, Gavi is using its know-how gained during COVID-19 on the frontline of the world's latest health emergency.
- Gavi-supported vaccination campaigns and routine introductions have virtually eliminated meningitis A in Africa, and with new technology coming online, the prospect of eliminating all strains of meningitis globally is within reach. We have the tools in place to make investments in global health security more effective than ever.

What's at risk:

- If Gavi doesn't meet its funding targets, difficult trade-offs will have to be made between protecting children by maintaining routine immunisation services and protecting our world by fighting outbreaks through our global stockpiles. A world without a fully funded Gavi would be a more dangerous world – for everyone.

#ForOurFuture

The best buy in global health

- Each vaccination doesn't just mean a potential life saved, it means parents not having to take time off work to look after their sick child; it means that child is more likely to go to school, to avoid life-changing disabilities and to fulfil a productive life. Multiplying this effect means healthier, more prosperous communities, societies and economies representing nearly half the world's population.
- This is why every dollar invested in vaccinations delivers US\$ 54 in wider economic benefits – one of the highest returns on investment in global health. In total, Gavi has delivered over US\$ 250 billion in economic benefits for the countries it supports since 2000.
- And this cost-effectiveness goes further – by working as an alliance, Gavi is able to reduce costs and make sure every dollar goes as far as possible in reducing the toll of disease. For every US\$ 1 invested in Gavi, 97 cents goes directly to supporting vaccine programmes.

What's at risk:

- Given Gavi's efficiency and low overheads, any reduction in funding cannot fail to have a real-world impact on its ability to save lives, protect our world, and deliver economic growth and sustainability to the countries it supports.

Harnessing the power of the private sector

- The Vaccine Alliance is unique in that the public and private sectors are equal partners in its mission to protect vulnerable children across the world.
- This means working in partnership with vaccine manufacturers to ensure healthy markets and maximise cost efficiency. It means harnessing the know-how of logistics experts like UPS, marketing powerhouses like Unilever and tech giants like ARM, among many others. And it means partnering to ensure the latest innovations are employed to serve its mission, from delivering vaccines by drone across Africa to rolling out groundbreaking biometrics in Bangladesh.
- This work now extends to supporting the sustainable growth of Africa's vaccine manufacturing base, through Gavi's African Vaccine Manufacturing Accelerator (AVMA). This new mechanism is designed to both contribute to healthy global vaccine markets, and benefit outbreak and pandemic prevention on the African continent.
- AVMA is just the latest innovative finance mechanism supporting the Gavi mission. The International Finance Facility for Immunisation (IFFIm) – one key example – has raised US\$ 9.7 billion in global capital markets through first-of-their-kind vaccine bonds to fund Gavi programmes.

What's at risk:

- No other development organisation leverages the power of the private sector the way Gavi does. Its record in innovative finance, private sector partnerships and market shaping delivers value for money for donors, encourages investment and innovation among manufacturers, and delivers new solutions to address long-standing challenges such as reaching zero-dose children.

#ForOurFuture

The next five years

- In the coming five years, Gavi's impact will be greater than ever – protecting more children against more diseases; protecting our world from the threat of pandemics; and protecting communities affected by conflict, climate change and other global challenges.
- The next five years will also see Gavi generate more economic impact than ever before, helping economies to grow, countries to become self-sufficient and families to prosper.
- To achieve this impact, Gavi needs at least US\$ 9 billion in new donor funding. This is how Gavi, the Vaccine Alliance can contribute to a stronger, safer world for us all in the coming five years.
- We can do this in **partnership with countries**, which will fund nearly 50% of the costs of their vaccines as they build and maintain sustainable national immunisation programmes.

SOCIAL POST SUGGESTIONS

- We call on donors to invest in @Gavi to support their goals to protect over 500 million children and save over 8 million lives from 2026-2030. #ForOurFuture
- @Gavi needs at least US\$ 9 billion in new donor funding to protect 500 million children and save over 8 million lives between 2026-2030. We urge world leaders to step up and invest #forourfuture
- Between 2000-2020, @Gavi helped vaccinate more than one billion children, saving over 17 million lives. We urge donors to support Gavi's 2026-30 goal to protect more children against more diseases faster than ever before
- Since @Gavi's inception in 2000, they have helped immunise more than 1.1 BILLION children around the world, averting >18.8 MILLION deaths. We call on donors to invest vital funding to build on this progress
- From 2000-2023, @Gavi supported 637 vaccine introductions and vaccination campaigns to protect children around the world against 16 infectious diseases! With donor support, Gavi will protect more people, against more diseases, faster than ever before. #forourfuture
- Thanks to @Gavi-supported vaccination programmes, 1.3 million future deaths were averted in 2023, which translates to over 2 lives saved every minute of the day! We urge donors to fully fund Gavi to continue these lifesaving efforts. #ForOurFuture
- Investments in immunisation are investments in healthier futures for children around the world. The case for world leaders is clear: fully fund @Gavi #forourfuture <https://bit.ly/3KQTVMQ>

#ForOurFuture

- Gavi's next strategic period up to 2030 calls for the world to invest, immunise and innovate #forourfuture. That's why we're supporting @Gavi's launch of their investment opportunity to usher in a new era of immunisation. <https://bit.ly/3KQTvMQ>
- Conflict, #climatechange and mass migration are fueling the risk of deadly outbreaks, which means the world needs @Gavi to be fully funded more than ever before. #ForOurFuture <https://bit.ly/3KQTvMQ>
- @Gavi's launch of their investment opportunity is a critical moment to highlight how funding immunisation secures healthier futures for children around the world. #VaccinesWork to protect communities, contain outbreaks and save lives. #ForOurFuture <https://bit.ly/3KQTvMQ>
- For every dollar invested in vaccination, \$21 is saved in health care costs, lost wages and lost productivity due to illness and death. As @Gavi launches their investment opportunity and usher in a new era of immunisation, we're calling for world leaders to fund lifesaving vaccines #ForOurFuture. <https://bit.ly/3KQTvMQ>
- Global immunisation efforts have saved at least 154 million lives over the past 50 years! We've seen what's #humanlypossible. Now it's time to build on this progress by fully funding @Gavi at their upcoming replenishment! <https://bit.ly/3KQTvMQ>

Humanly Possible

- Immunisation has saved six lives a minute. Every minute. For five decades. Now it's time for world leaders to invest in immunisation by fully funding @Gavi at their replenishment. #HumanlyPossible <https://bit.ly/3KQTvMQ>
- In the last 50 years, immunisation has decreased infant mortality by 40%. That means more children now reach their 5th birthday than ever before. World leaders must build on this incredible progress by funding @Gavi to invest in immunisation and show what is #HumanlyPossible <https://bit.ly/3KQTvMQ>
- Vaccines save lives and build futures. We're proud to work with @Gavi and together we have protected millions of children. But millions still miss out. It's time to look to the future and fully fund Gavi to invest in the future of immunisation. #HumanlyPossible <https://bit.ly/3KQTvMQ>

Key hashtags

- #ForOurFuture
- #VaccinesWork
- #HumanlyPossible

#ForOurFuture

DIGITAL ASSETS

Infographics

Infographics from Gavi's Investment Opportunity: [link](#)

Quote cards

Quote cards from countries, private sector, civil society and other partners: [link](#)

Theme week vignettes

Vignettes spotlighting a unique theme of impact in Gavi implementing countries: [link](#)

Country voices

- Images and quote cards of health workers and people from Gavi implementing countries: [link](#)
- Videos of health workers and people receiving vaccinations: [link](#)

RESOURCES

MEDIA & CONTENT LIBRARY

- Photos from pledge announcements: [link](#)
- Photos & B-roll of immunisation in action: [link](#)

VOICES OF SUPPORT

Why it matters: Voices of Support

Quotes and video content of leaders from government, partner organisations, civil society and business expressing why immunisation matters: [link](#)

#ForOurFuture

About Gavi, the Vaccine Alliance

What is Gavi?

- Gavi, the Vaccine Alliance was established in 2000 as a **public-private partnership** that helps vaccinate more than half the world's children against some of the world's deadliest diseases.
- Gavi's mission is **to save lives and protect people's health by increasing equitable and sustainable use of vaccines**.
- Gavi plays a key role in **improving global health security** by supporting health systems and funding global stockpiles for Ebola, cholera, meningococcal and yellow fever vaccines.
- Gavi is focused on **protecting the next generation**, above all the zero-dose children who have not been reached by routine immunisation services.

What is Gavi's impact?

- **Helped to immunise over 1 billion children** since 2000 and has supported more than 1.8 billion vaccinations globally through preventive vaccination campaigns.
- **This has helped to reduce vaccine-preventable child deaths by 70%** in Gavi-supported lower-income countries; avert 18.8 million future deaths; and halve mortality among children aged under five.
- **An outbreak and pandemic response organisation supporting global health security:**
 - Global stockpiles for yellow fever, Ebola, cholera and meningococcal vaccines – with others planned
 - 2 billion COVID-19 vaccines to 146 economies helping avert an estimated 2.7 million deaths in AMC lower-income participating economies through COVAX
 - Day Zero Pandemic Financing Facility for Vaccines to ensure critical funding for future responses
- **Made vaccines more affordable and more accessible:** The cost of fully immunising a child with pentavalent, pneumococcal and rotavirus vaccines has fallen by approximately 60% since 2010.
- **Supported 19 countries to transition** to fully self-financing their immunisation programmes. Over US\$ 1.7 billion in co-financing contributions from Gavi-supported countries since 2008.
- Protects against 20 infectious diseases, up from 6 during the 2001–2005 period.
- **Delivered US\$ 250 billion in economic benefits** through immunisation programmes in Gavi-supported lower-income countries.

What is Gavi's 2026–2030 Investment Opportunity?

- Gavi's Investment Opportunity (IO) outlines the **projected impact of the Alliance's programmes from 2026 to 2030 and how much funding is required to achieve these goals**.
- The IO looks at the number of children who could be vaccinated, lives that could be saved, growing number of diseases against which vaccines are now available and other factors such as:
 - Expanded stockpiles to cope with expected increases in disease outbreaks
 - Key emergency response mechanisms to contain emerging health threats
 - The impact of climate change
 - The economic benefits of immunisation
- **The Investment Opportunity makes the case to the global community, particularly donors, that investment in immunisation is one of the most cost-effective and impactful interventions for health and economic development.**

DEEP DIVE MESSAGES

Global health security and outbreaks

- With rising outbreaks and epidemics, fuelled by climate change, population growth and growing levels of fragility and conflict, the question is no longer if another pandemic will strike, but when.
- A series of deadly outbreaks and pandemics, from H1N1 to Ebola and then COVID-19, have made it clear: diseases do not respect borders. Gavi's vaccines make the world safer by reducing the spread of disease in some of the poorest countries in the world. Over half the vaccines in Gavi's portfolio will help countries adapt to the impacts of climate change and reduce the demand for antibiotics – countering the 'silent' pandemic of antimicrobial resistance (AMR).
- During the 2026–2030 period, Gavi will make its largest investment in vaccine programmes and stockpiles for outbreak-prone diseases including Ebola, cholera, meningitis and yellow fever, and support to the Measles & Rubella Partnership (US\$ 10 million a year), providing critical capacity to respond to over 150 outbreaks.
- For more than two decades, Gavi's support for routine immunisation programmes and to combat disease outbreaks has served as a foundation for global health security.
- Routine immunisation programmes not only help to build resilient and sustainable health systems, they also establish the essential infrastructure required to deliver vaccines during dangerous outbreaks. Gavi's work is not just a local or regional effort, but a global public good directly contributing to global health security.
- To ensure greater coherence as the world builds the systems required to prepare for and respond to future pandemics, Gavi will ensure its 2026–2030 strategy strengthens the outcomes of discussions on the future global health security landscape.
- As part of this effort, financing tools such as Gavi's Day Zero Financing Facility for Pandemics (DZF) – with US\$ 2.5 billion in surge capacity – will ensure immediate funding can be directed to support equitable access to vaccines for lower-income countries in the next pandemic.
- The facility will be deployed in support of the final outcomes of negotiations on the Pandemic Agreement and the updated International Health Regulations.
- A coalition of vaccine partners will actively contribute to the WHO-led Interim Medical Countermeasures Network. Gavi will continue to work with countries to build resilient systems and boost their capacity to detect and diagnose vaccine-preventable diseases, working with the Pandemic Fund.

Co-financing and sustainability

- Over the past 20 years, Gavi's market shaping efforts have transformed the global vaccine landscape. The creation of Gavi, with the true spirit of public-private partnership, helped create an alternative model in service of lower-income countries – with pooled procurement facilitated by Gavi on behalf of implementing countries. This meant manufacturers could invest in a new market, with large volumes, but at lower prices.
- At the core of this market shaping approach is affordable yet sustainable pricing. It means Gavi's resources, from both donor funds and country co-financing, are used efficiently for the greatest long-term impact.
- Country ownership of national immunisation programmes is at the heart of everything Gavi does. It has one of the most successful models of encouraging national investment and domestic resource mobilisation across global health. Every country makes a commitment to funding part of their vaccine programmes, with the amount increasing over time in line with their ability to pay. Ultimately, with carefully targeted support, countries transition from Gavi and fully fund their own vaccine programmes.

#ForOurFuture

- Countries will play their part, for the first time contributing nearly 50% of their own routine vaccine costs.
- Nineteen countries supported by Gavi have now fully transitioned out of Gavi support and fund their own vaccine programmes.
- By the end of 2025, countries supported by Gavi will have invested around US\$ 5.2 billion in their vaccine programmes since 2008.
- In the face of fiscal challenges, climate change, conflict and instability, most Gavi-supported countries maintained or increased domestic resources for co-financing of Gavi-supported vaccines in 2023, bringing to US\$ 1.7 billion their total contribution since the introduction of the co-financing policy in 2008.
 - US\$ 215 million was contributed by countries towards the co-financing of Gavi-supported vaccines in 2023 – the highest amount yet and a testament to country ownership and the long-term financial sustainability of Gavi-supported vaccines.
 - 55 vaccine programmes originally introduced with Gavi funding are now self-financed by countries as of 2023, up from 40 in 2018.
 - 100% of countries fully met their 2023 co-financing obligation – except four waivers for humanitarian crises.
- During the 2026–2030 strategic period, countries will make more contributions towards the cost of their vaccines than ever before – over US\$ 4 billion in co-financing and self-funded vaccine programmes

Innovative financing

- The International Finance Facility for Immunisation (IFFIm) has been a critically flexible tool for Gavi in times of extraordinary need with high levels of unpredictability, including in response to the COVID-19 pandemic – enabling surge funding when needed, while underpinning Gavi's early efforts in developing its cohesive suite of tools in service of global pandemic response led by the G7.
- In the 2021–2025 strategic period, IFFIm maximised frontloading and flexible financing for Gavi's core programmes; it was also one of the earliest funding sources available to Gavi for the COVID-19 pandemic response.
- As Gavi prepares to achieve its ambitious 2026–2030 goals, IFFIm's proven model will be critical to frontload resources to enable the rapid introduction and scale-up of new breakthrough vaccines, including malaria and hexavalent vaccines; allow Gavi to enter into long-term purchase agreements with suppliers at lower costs than would be otherwise possible; provide flexibility to adapt to changes in country needs; and quickly respond to unexpected events, such as new outbreaks.
- To achieve this, Gavi is seeking new long-term donor pledges allowing IFFIm to contribute around 20% of Gavi needs during the 2026–2030 period.
- Taking into consideration assured resources of US\$ 665 million, this represents pledges to IFFIm with a real value of US\$ 1.7 billion.
- Since 2011, the Gavi Matching Fund, an innovative financial mechanism, has fuelled expanded private sector contributions to immunisation, and played a critical role to catalyse private sector funding for both Gavi's core and COVAX programmes. To date, it has spurred investments worth over US\$ 500 million across 35 partnerships.
- For the 2026–2030 period, an increase to the Gavi Matching Fund of at least US\$ 100 million will catalyse more cash contributions from a diverse set of private sector partners.

Public-private partnership

- As a public-private partnership (PPP), Gavi's unique model was designed to unlock the comparative advantages of its broad array of stakeholders. In this same spirit of partnership, Gavi today works alongside new partners in ways that strengthen health systems, create efficiencies and open up entry points for other vital programmes.
 - *Proof point:* Empowering local actors and a gender-focused approach to immunisation will target hard-to-reach communities. Between 2026 and 2030, Gavi will facilitate hundreds of millions of contacts between families and health services through routine vaccination.
 - Gavi and the Global Fund work together closely to enhance malaria prevention in sub-Saharan Africa, by ensuring access to all tools and interventions.
- Delivering impact through private sector engagement:
 - Toyota Tsusho's refrigerated vaccine transport vehicles reduced operational costs by 63%, by improving fuel efficiency and optimising route planning in Niger, Burkina Faso & Senegal.
 - Zipline's drones have delivered more than 17 million vaccine doses to hard-to-reach places, contributing to strengthened supply chains.
 - Mobile health solution M-Vaccin is benefiting over 100,000 caregivers and children in Côte d'Ivoire.
 - The Children's Investment Fund Foundation helped reach 140,000 Ethiopian under-served children through an integrated immunisation, nutrition and social protection programme
 - HETA aims to electrify and digitally connect at least 10,000 health facilities in sub-Saharan Africa by 2030.
 - More than 34,000 state-of-the-art remote temperature monitoring devices (RTMD) deployed to prevent vaccine damage from excessive heat or cold.
 - Harnessing big data analytics to sharpen the accuracy of vaccine planning to reach under-immunised children and increase the coverage of zero-dose children up to three times.
 - In Ethiopia, girls who had consumed Girl Effect content were 60% more likely to intend to get vaccinated against HPV.
 - In India, the partnership with Unilever Lifebuoy brought about a 30% increase in uptake of rotavirus and measles vaccines among children under two.
 - INFUSE 2024 is actively seeking innovative solutions uniquely positioned to enhance health systems, enabling them to effectively manage resilient and climate-adaptive responses to climate threats.

Shaping global markets

- Gavi's market shaping efforts make life-saving vaccines and other immunisation products more accessible and affordable for lower-income countries.
- Through Gavi's market shaping efforts, the number of manufacturers supplying prequalified Gavi-supported vaccines remained at 19 in 2023 (with more than half based in low- and middle-income countries) – compared with 5 in 2001.
- 10 markets for and immunisation products exhibited acceptable levels of healthy market dynamics in 2023, meeting the target for the year.
- 10 innovative products were within the pipeline of commercial-scale manufacturers in 2023, continuing to exceed the Alliance target of 8 by 2025 well ahead of schedule.

#ForOurFuture

- 1 new product with improved characteristics was newly offered to Gavi-supported countries in 2023, keeping the Alliance on track for its 2025 target: multivalent meningococcal conjugate vaccine (MMCV), the first conjugate vaccine to protect against the five predominant serogroups of meningococcal meningitis in Africa.
- A price of US\$ 3 per dose was secured for the new 5-in-1 meningococcal conjugate vaccine for the emergency stockpile – more than US\$ 10 lower than previous vaccines.
- The cost of fully immunising a child with pentavalent, pneumococcal and rotavirus vaccines has fallen by approximately 60% since 2010.
- The number of vaccine markets for lower-income countries designated as 'healthy', whereby supply availability and supply security of appropriate products are improved with a robust supply base, has increased from one in 2015 to ten in 2023.
- The African Vaccine Manufacturing Accelerator (AVMA) is a flagship financing and market shaping instrument to support the sustainable growth of Africa's manufacturing base.

African Vaccine Manufacturing Accelerator (AVMA)

- The African Vaccine Manufacturing Accelerator (AVMA) is an innovative financing mechanism, designed by Gavi in close collaboration with the African Union, Africa Centres for Disease Control and Prevention (Africa CDC) with extensive consultations with partners, donors, industry, civil society and other stakeholders. AVMA aims to help vaccine manufacturers in Africa to scale up production and foster regional diversification of vaccine manufacturing.
- At present, demand for vaccines in Africa is valued at over US\$ 1 billion annually, with this figure projected to grow along with the continent's population over the next several decades. Africa already accounts for around 20% of the world's population, yet the continent's vaccine industry provides only around 0.1% of global supply
- AVMA is playing a formative role in helping build a high-quality, sustainable manufacturing sector capable of supporting the African Union's ambition to manufacture at least 60% of the total vaccine doses required on the continent by 2040.
- With a commitment of up to US\$ 1.2 billion over ten years, AVMA supports crucial development stages, offsetting high start-up costs. AVMA offers a 'pull financing mechanism' by providing downstream incentives to manufacturers to level the playing field until they can build economies of scale for sustainability.
- By 2035, AVMA aims to support the procurement of at least 800 million vaccine doses made in Africa, across at least four vaccine manufacturers, using three different vaccine technology platforms. Taken together, the facilities supported should have the capacity for 700 million doses a year to be repurposed in a future pandemic – around 50% of Africa's population.

Value for money and return on investment (ROI)

- US\$ 54 for US\$ 1 spent: A study covering 73 Gavi-supported countries shows that, for every US\$ 1 spent on immunisation in the 2021–2030 period, US\$ 21 are saved in health care costs, lost wages and lost productivity due to illness and death. When considering the value people place on lives saved by vaccines – which is likely to include the value of costs averted plus the broader societal value of lives saved and people living longer and healthier lives – the return on investment is estimated to be US\$ 54 per US\$ 1 spent.

#ForOurFuture

- From 2000–2023, Gavi-supported immunisations generated more than US\$ 134 billion in economic benefits in Gavi-supported countries in Africa – and more than US\$ 250 billion across Gavi-supported countries globally (all in 2018 US\$).
- With Gavi, more than 97 cents out of every US\$ 1 goes to supporting vaccine programmes. That efficient delivery model will continue into 2026–2030.
- The overhead ratio within the Secretariat will remain at or below 3% of our total budget, driven by the implementation of an ambitious operational excellence programme – simplifying and streamlining the Secretariat’s ways of working but, more importantly, helping transform how Gavi provides timely support to countries and partners.

Human papillomavirus (HPV) vaccine and gender equality

- Cervical cancer is the fourth most common cause of cancer and cancer death among women worldwide. The disease continues to unnecessarily kill almost 350,000 women every year, with more than 90% of these deaths occurring in low- and middle-income countries.
- Yet cervical cancer is highly preventable with the effective HPV vaccine.
- For every 1,000 girls vaccinated, almost 18 deaths are prevented, making it one of the most impactful vaccines in Gavi’s portfolio.
- Gavi is committed to including the HPV vaccine as part of a holistic package of care for adolescent girls, for instance on nutrition and sexual and reproductive health, delivered in collaboration with partners.
- The 2023 revitalisation of Gavi’s HPV vaccine programme yielded significant gains: countries fully immunised more than 14 million girls with Gavi support in 2023 – more than the previous ten years combined – for a total of more than 27.3 million girls reached since 2014. And the 57 Gavi-supported countries (Gavi57) substantially improved coverage: by 8 percentage points (pp) to 20% for the first dose (HPV1) and by 8pp to 16% for the last dose in the schedule (HPVC).
- Thanks to the Alliance’s market shaping activities and focused efforts with manufacturers, greater availability of the HPV vaccine will allow over 120 million girls to be vaccinated in 2026–2030, saving more than 1.5 million lives.
- Empowering women and supporting gender equality: Tackling gender inequality means improving social, health and economic outcomes. In its next strategic period, Gavi will continue to sharpen its focus on gender to overcome barriers to access and help empower the predominantly female health care workforce.
 - *Proof point:* Millions of young women and girls will be protected from HPV between 2026 and 2030.
 - *Proof point:* Gavi is helping make health services more accessible and safer for women and girls; supporting the recruitment and training of women health workers and addressing their specific needs in the workplace; and providing services at times and places convenient for mothers, while also engaging fathers.
 - *Proof point:* Working directly with fathers in Togo has helped to reach more than 80% of children previously missing vaccination in targeted communities, while working with local and religious leaders in Papua New Guinea has improved the safety of women health workers.
- Gavi is committed to including the HPV vaccine as part of a holistic package of care for adolescent girls, for instance on nutrition and sexual and reproductive health, delivered in collaboration with partners.

Malaria vaccine programme

- The Gavi Board made history in December 2021 by approving funding to support the roll-out of the world's first malaria vaccine (RTS,S/AS01e vaccine) – nearly 35 years in development – in sub-Saharan Africa in 2022–2025. In October 2023, the WHO Strategic Advisory Group of Experts on Immunization (SAGE) recommended that the second malaria vaccine (R21/Matrix-M vaccine) be approved for use in children at risk of *P. falciparum* malaria; and it has dramatically improved the supply availability for roll-out of malaria vaccine programmes.
- According to WHO, the vaccine is estimated to save 1 life for every 200 children vaccinated. Gavi's malaria vaccine programme will protect children against a disease that kills hundreds of thousands in Africa every year.
- By end 2024, 17 countries in Africa had introduced malaria vaccine into their national immunisation programme with Gavi support.
- In the 2026–2030 period, Gavi will help vaccinate at least 50 million children with the recommended four doses of malaria vaccines.
- The malaria vaccine can reduce under five child mortality by 13%. When the full mix of malaria interventions (including vaccines, bed-nets, indoor spraying and others) are used together, additional analysis shows the burden of malaria can be reduced by as much as 92%.

Climate and health

- Gavi implementing countries are disproportionately affected by the changes in the world's temperature. Climate shocks such as floods and droughts threaten health systems, making vaccine delivery even more challenging, and urbanisation is only compounding impacts. Waterborne diseases like cholera are becoming more common. So are those driven by animals or insects, like malaria or yellow fever.
- In the next strategic period, Gavi will deepen its focus on helping countries adapt to the impacts of climate change. To provide more protection against climate-sensitive diseases, Gavi will ramp up its malaria vaccine programme; introduce a vaccine against dengue; and expand preventive campaigns and vaccine stockpiles against diseases like cholera and yellow fever.
- As the climate crisis and rising antimicrobial resistance (AMR) continue to place great strain on the health systems of lower-income countries, vaccination is one of the strongest and most effective interventions. Over half of Gavi's vaccine portfolio will help countries adapt and respond to these twin threats.
 - *Proof point:* Cholera, Japanese encephalitis, malaria, meningitis, typhoid and yellow fever are just some of the climate-sensitive diseases in Gavi's portfolio.
 - *Proof point:* Gavi's efforts over the next strategic period can help turn the tide against AMR: Hib, pneumococcal, rotavirus and typhoid vaccination in Gavi-eligible countries could significantly reduce the use of antibiotics.
 - *Proof point:* Gavi works with countries to adapt routine immunisation programmes so they can be sustained through outbreaks and other health emergencies.

Science and innovation

- Gavi will use its market power to promote innovation from manufacturers while reducing prices across 50% of the vaccine portfolio between 2026 and 2030 – all while keeping vaccine markets stable and healthy.
- Immunisation is key to the achievement of UN Sustainable Development Goal (SDG) Goal 9. Industry, innovation and infrastructure: Gavi makes vaccine markets work better by attracting more suppliers, dramatically reducing vaccine prices and ensuring more equitable and sustainable access to vaccines and other innovative products that meet lower-income countries' needs. Since our inception in 2000, we have contributed to a significant increase in new manufacturers supplying vaccines for Gavi and the majority of the vaccine doses we procure are manufactured in developing countries.
- Gavi will continually scan the horizon for technological advancements that make it easier to deliver vaccines and reach more people with more impact. Microarray patches (MAPs) vaccines delivered by a patch, not a needle – are one example of a game-changing industry innovation that could make it simpler to respond to outbreaks and reach missed communities.
- Gavi's attention will not just remain on the relatively short horizon of the next strategic period. The world is currently experiencing a revolution in vaccine technology, with the prospect of exciting new vaccines and innovations to save more lives.
- Gavi is the only organisation that has the right blend of partnerships, notably with UNICEF and WHO, to provide the technical, scientific and financial skills to drive the long-term commitments – which often extend to more than ten years – required to shape complex new markets and ensure adequate supply to lower-income countries at the right price.

Universal Health Coverage (UHC)

- In 2026–2030, Gavi will protect the future by facilitating over 1.4 billion individual contacts between families and health services, enabling more integrated primary health care and Universal Health Coverage.
- As an Alliance, Gavi is ideally placed to bring together actors across global health and build enhanced partnerships to strengthen health systems around countries' own priorities in the spirit of the Lusaka Agenda – strengthening primary health care and contributing to Universal Health Coverage (UHC).
- Immunisation is a fundamental component of primary health care and serves as a platform for other critical services, making it a cornerstone of Universal Health Coverage. Preventing disease through immunisation also significantly drives efficiency, reducing national health care costs and alleviating further stress on health systems, driving long-term impact and cost savings.

Zero-dose children

- Population growth, increased conflict and fragility, migration, and climate change are making it harder to reach under-served communities with immunisation.
- Despite significant progress, over 11 million children a year born in lower-income countries still don't receive even a single vaccine.
- In the next strategic period, Gavi will accelerate its work to reduce the number of so-called 'zero-dose' children – contributing to the Immunization Agenda 2030 target of a 50% decrease.

#ForOurFuture

- To do this, Gavi will sharpen its focus on gender and other demand-related barriers and engage more deeply with communities and civil society organisations.

Health system strengthening (HSS)

- Over the next five years, Gavi will protect people, protect communities and protect the world by continuing to work with countries to improve the health systems needed to ensure vaccines can reach every child
- As of 2023, approximately 46 Gavi-supported countries are using DHIS2, the world's largest health management information system, for immunisation – an increase of 6 over 2022.
- The growing demand for digital solutions spurred Gavi investments across various digital health information (DHI) priority areas: as of 2023, 26 countries are scaling up target software standards (TSS)-compliant electronic logistics management information system (eLMIS) solutions – improving stock visibility and supply chain digitisation; 10 countries implemented real-time national vaccination campaign planning and monitoring systems; and 5 countries developed detailed DHI roadmaps for immunisation.
- Alongside the Global Financing Facility (GFF) and the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund), Gavi is also scaling up coordination on health system strengthening investments and supporting simplified country-facing processes, taking lessons from a set of volunteer 'pathfinder' countries.

Immunisation and the Sustainable Development Goals (SDGs)

- Immunisation is one of the best buys in global health and key to the achievement of the UN Sustainable Development Goals (SDGs), including but not limited to the following goals:
 - **Goal 1. No poverty:** Immunisation provides a platform for delivering nutrition interventions and work hand in hand with good nutrition to help reduce child mortality. Vaccine-preventable diseases could tip children into a malnourished state as they impair the absorption of essential nutrients. Malnourished children are more likely to die from infectious diseases such as diarrhoea, measles and pneumonia, many of which can be prevented by vaccines.
 - **Goal 2. Zero hunger:** Immunisation and good nutrition go hand in hand. Vaccine-preventable diseases often tip marginally nourished children into a malnourished state. Malnourished children are more likely to die from infectious diseases such as diarrhoea, measles and pneumonia, many of which can be prevented by vaccines.
 - **Goal 3. Good health and well-being:** Immunisation is one of the most cost-effective ways to save lives and promote good health and well-being. Every year, vaccines save 2-3 million lives, and millions more are protected from disease and disability. It routinely reaches more households than any other health service and brings communities into regular contact with the health system. This provides an effective platform to deliver other primary health care services and upon which to build universal health coverage.
 - **Goal 4. Quality education:** Immunisation increases educational attainment since vaccinated children learn more while they are able to go to school and perform better, positively impacting on cognitive development as well as long-term productivity. Moreover, schools are a platform for health promotion, delivery of vaccines and other health services. The benefits flow both ways: children of educated parents have a greater chance of being immunised and well-nourished and thus enjoy better health.
 - **Goal 5. Gender equality:** Immunisation is a gender-equal intervention. Globally, girls and boys are immunised at similar rates. However, there are variations at sub-national levels and in some countries because a range of different barriers inhibit women's ability to access healthcare for their children. Gavi

#ForOurFuture

supports countries to make focused efforts to identify and address gender-related barriers to immunisation services, such as through training female health workers, as empowering women is critical to improving child vaccination coverage.

- **Goal 6. Clean water and sanitation:** Vaccines, along with clean water, sanitation and hygiene (WASH), are proven interventions to prevent diarrhoeal diseases, a leading cause of child mortality in developing countries. Investments in oral cholera and rotavirus vaccines, WASH and health systems form an integrated approach to help eliminate diarrhoeal disease.
- **Goal 7. Affordable and clean energy:** Immunisation brings newer, cleaner and more sustainable technology to developing countries' health systems. For instance, Gavi's cold chain equipment optimisation platform gives countries access to solar and energy efficient refrigeration, which is not only more reliable and cost-effective but also more environmentally friendly. Our support includes vaccine monitoring devices that ensure optimum energy usage and reduce wastage.
- **Goal 8. Decent work and economic growth:** Investment in human capital can dramatically strengthen a country's competitiveness. Vaccinated, healthy children grow into a productive workforce and become strong contributors to the economy. In addition, healthy children free up parents' time so they are able to work. In Gavi-supported countries, every US\$ 1 spent on immunisation generates US\$ 54 in broader societal benefits of people living longer and healthier lives.
- **Goal 9. Industry, innovation and infrastructure:** Gavi makes vaccine markets work better by attracting more suppliers, dramatically reducing vaccine prices and ensuring more equitable and sustainable access to vaccines and other innovative products that meet developing countries' needs. Since our inception in 2000, we have contributed to a significant increase in new manufacturers supplying vaccines for Gavi and the majority of the vaccine doses we procure are manufactured in developing countries.
- **Goal 10. Reduced inequalities:** Immunisation protects the health of communities, reduces the number of people forced into poverty, and gives children an equal chance of a healthier and more productive future. By focusing on the under-served communities and unimmunised ("zero dose") children in the poorest and most marginalised populations, especially the urban poor and those living in remote rural settings and conflict areas, Gavi brings immunisation and primary health care services to those furthest behind.
- **Goal 11. Sustainable cities and communities:** By 2050, nearly 70% of the global population will be living in urban areas. The number of people living in slums or informal settlements has also grown to over 1 billion, many of whom lack access to basic health services. Strengthening urban immunisation programmes protects them against the increased risk of disease outbreaks and is an opportunity to bring integrated preventative services to urban and underserved communities.
- **Goal 13. Climate action:** The impact of climate change cuts across health and well-being, livelihood, and security of people, particularly for the poorest and most vulnerable communities, such as people on the move. Immunisation is critical to building people's and systems' resilience to and reducing the risk of outbreaks due to climate-sensitive diseases, such as yellow fever, cholera and Ebola, particularly in urban, fragile and post-disaster settings.
- **Goal 16. Peace, justice and strong institutions:** Effective, safe, and people-centred health systems are the backbone of social institutions in every country, and immunisation is often the first point of contact between these systems and the population. Through Gavi support, countries' efforts to improve equitable access to vaccines contributes to building public trust, stronger social cohesion, peaceful and inclusive societies.
- **Goal 17. Partnerships for the goals:** Leveraging the comparative advantage of each partner, the Vaccine Alliance's innovative public-private partnership model has transformed global progress by accelerating

#ForOurFuture

equitable and sustainable access to vaccines both at scale and pace. Since 2000, Gavi support has helped countries immunise more than 1.1 billion children and prevented more than 18.8 million future deaths, helping to halve child mortality in 78 lower-income countries.

Immunisation and nutrition

- Immunisation is key to the achievement of the UN Sustainable Development Goal (SDG) Goal 2. Zero hunger: immunisation and good nutrition go hand in hand. Vaccine-preventable diseases often tip marginally nourished children into a malnourished state. Malnourished children are more likely to die from infectious diseases such as diarrhoea, measles and pneumonia, many of which can be prevented by vaccines.
- Infection and malnutrition (November 2023 [report](#) by Gavi and the Eleanor Crook Foundation.)
- Immunisation and nutrition programmes are among the most cost-effective approaches to help children survive and thrive, but despite some successes in scaling these programmes, too many children still do not have access to the services they need – and in many cases, the children with the greatest risk of malnutrition are the same children who are under-immunised.
- Gavi today works alongside partners in ways that strengthen health systems, create efficiencies and open up entry points for other vital programmes, such as nutrition to reduce food insecurity.
- The Eleanor Crook Foundation in partnership, with Gavi, will implement a research project, Nutrivax, that aims to generate evidence on the interplay between nutrition services and demand for vaccines in Nigeria.
- In collaboration with the Children's Investment Fund Foundation, 140,000 Ethiopian under-served children have been reached through an integrated immunisation, nutrition and social protection programme.